Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report"

World J Urol. 2022 May;40(5):1251-1252. doi: 10.1007/s00345-022-03968-7. Epub 2022 Feb 22.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Carcinoma, Transitional Cell* / drug therapy
  • Carcinoma, Transitional Cell* / pathology
  • Female
  • Humans
  • Male
  • Mitomycin / therapeutic use
  • Urinary Bladder Neoplasms* / pathology
  • Urothelium / pathology

Substances

  • Mitomycin